The meningococcal serogroups that cause in the US on most common diseases are the serogroups B, C and Y. The serogroups A and W cause disease outside the United States. Current vaccines are directed against some but not all of these serogroups.
For more information, s. Meningococcal ACIP Advisory Committee for Immunization Practices) Vaccine Recommendations and Infant Meningococcal Vaccination update. The meningococcal serogroups that cause in the US on most common diseases are the serogroups B, C and Y. The serogroups A and W cause disease outside the United States. Current vaccines are directed against some but not all of these serogroups. For serogroups ACWY (quadrivalent): meningococcal conjugate vaccines (MCV4): MenACWY-D (Menactra®) or CRM-MenACWY (Menveo®) meningococcal polysaccharide vaccine (MPSV4 [Menomune®]) (for serogroups CY bivalent ): Hib-MenCY-TT (MenHibrix®), in the tetanus toxoid, and Haemophilus influenzae type b capsular polysaccharide conjugated to meningococcal serogroups-C and Y polysaccharides. For serogroup B (monovalent): meningococcal serogroup B vaccine (recombinant vaccine, which is composed of two LP2086 antigens) Indications The meningococcal vaccine is a routine childhood vaccination, the young is administered, preferably in the age of 11 or 12 years, with a booster dose at the age of 16 years (see table: Recommended vaccination schedule for the age of 7-18 years). It is also recommended for younger children at high risk for infection (see Table: Recommended vaccination schedule for the age of 0-6 years). MenACWY conjugate vaccines are recommended for adults who have conditions that increase the risk of meningococcal infection, such as anatomic or functional asplenia Persistent Komplementkomponentenmängel research in a microbiological laboratory routinely excessive exposure to isolates of N. meningitidis Military recruitment travel or residence in endemic areas First year of stay in a dormitory when the students ? 21 years old and have not yet received the dose on or after their 16th birthday exposure to an outbreak that can be attributed to a vaccine serogroup when students of the first semester only one dose of the vaccine have received before their 16th birthday, aged ? 21 years, they should have a booster dose at baseline he hold. MenACWY is for all young people (aged 11 to 18), including those with HIV infection, is recommended. In other cases it is, however, only indicated when people are exposed to HIV infection for other reasons increased risk. MenACWY is for people aged 11 to 55 years and for those> 55 years who have previously received MenACWY and need a booster or more doses of the vaccine are preferred. Revaccination with MenACWY every 5 years are recommended for adults who have previously received MenACWY or MPSV4 and continue to have an increased risk of infection (eg. As adults with anatomic or functional asplenia or persistent Komplementkomponentemängeln, microbiologists). MPSV4 is preferred for persons> 55 years who have not received MenACWY previously and a single dose only need (for. Example, travelers). The new meningococcal serogroup B vaccine is indicated for certain people aged between 10 and 25 years; the specific indications have not yet been published, but it is likely to be administered jointly with the meningococcal vaccine on a similar schedule. Contraindications and precautions The main contraindication is a severe allergic reaction (eg., Anaphylaxis) after a previous dose or to a vaccine component The most important precaution is Moderate or severe illness with or without fever (vaccination, if possible postponed until the disease is over) dosage and administration The dose is 0.5 ml in the s.c. for MenACWY and 0.5 ml for MPSV4. Two doses of MenACWY administered at a distance of ? 2 months and followed by a booster every 5 years are required with anatomical or functional Asplenie or persistent Komplementkomponentenmängeln in adults. Adolescents (age 11 to 18 years) with an HIV infection are routinely vaccinated with a 2-dose primary immunization; the doses are separated by 8 weeks. A single dose of the meningococcal vaccine is microbiologists that are routinely exposed to isolates of N. meningitidis, recruits in the military, individuals at risk during an outbreak, which is due to a vaccine serogroup, and those traveling to endemic areas or live there administered. If the risk still exists (e.g., as for microbiologists to continue the work with N. meningitidis), booster vaccinations are necessary. Side effects Side effects are usually mild. They include pain and redness at the injection site, fever, headache and fatigue.